Advertisement

Mycopathologia

, Volume 169, Issue 3, pp 193–199 | Cite as

Clinical Itraconazole-Resistant Strains of Aspergillus fumigatus, Isolated Serially from a Lung Aspergilloma Patient with Pulmonary Tuberculosis, can be Detected with Real-Time PCR Method

  • Hui Xu
  • Wei Chen
  • Lijuan Li
  • Zhe Wan
  • Ruoyu Li
  • Wei Liu
Article

Abstract

The invasive aspergillosis, which is commonly caused by Aspergillus fumigatus (A. fumigatus), has increased in recent years. Traditional methods for finding out antifungal resistant strains would take more than 2 weeks, which cannot satisfy the needs of rapid detection. In this study, a real-time PCR method for detection of the serial itraconazole-resistant strains of A. fumigatus isolated from a lung aspergilloma patient was developed. The results showed that the TacMAN-MGB probes, which were covered the loci Gly54, Leu98, Gly138, and Met220 of the enzyme CYP51A coded by the gene cyp51A, as well as the 34-bp tandem repeated sequence in the promoter region (−288 and −322 from the start codon) of this gene, could detect the serial itraconazole-resistant strains of A. fumigatus in our study. Besides, this method takes just 6 h to complete the whole detection.

Keywords

Aspergillus fumigatus Itraconazole resistance Real-time PCR cyp51A mutation 

Notes

Acknowledgments

This work was supported by National Natural Science Foundation of China (30500027) and the Key Project of Chinese Ministry of Education (107002) to Wei Liu and was also supported by the Project of Ministry of Health of the People’s Republic of China (200802026) and the Project of the Ministry of Science and Technology of the People’s Republic of China (2008ZX10004-002) to Ruoyu Li.

References

  1. 1.
    Qiao JJ, Liu W, Li RY. Antifungal resistance mechanisms of Aspergillus. Nippon Ishinkin Gakkai Zasshi. 2008;49(3):157–63.CrossRefPubMedGoogle Scholar
  2. 2.
    Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis. 2002;15(6):569–74.PubMedGoogle Scholar
  3. 3.
    Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041–50.CrossRefPubMedGoogle Scholar
  4. 4.
    Maschmeyer G, Haas A, Cornely OA. Invasive Aspergillosis—Epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007;67(11):1567–601.CrossRefPubMedGoogle Scholar
  5. 5.
    Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis. 2008;46(3):327–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Segal BH. MEDICAL PROGRESS Aspergillosis. N Engl J Med. 2009;360(18):1870–84.CrossRefPubMedGoogle Scholar
  7. 7.
    Snelders E, van der Lee HAL, Kuijpers J, Ajmm Rijs, Varga J, Samson RA, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLos Med. 2008;5(11):1629–37.CrossRefGoogle Scholar
  8. 8.
    Chen J, Li HM, Li RY, Bu DF, Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother. 2005;55(1):31–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Rodriguez-Tudela JL, Alcazar-Fuoli L, Alastruey-Izquierdo A, Monzon A, Mellado E, Cuenca-Estrella M. Time of incubation for antifungal susceptibility testing of Aspergillus fumigatus: Can MIC values be obtained at 24 hours? Antimicrob Agents Chemother. 2007;51(12):4502–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat. 2005;8(6):344–58.CrossRefPubMedGoogle Scholar
  11. 11.
    Nascimento AM, Goldman GH, Park S, Marras SAE, Delmas G, Oza U, et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother. 2003;47(5):1719–26.CrossRefPubMedGoogle Scholar
  12. 12.
    Arias A, Arevalo MP, Andreu A, Rodriguez C, Sierra A. In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents. Mycoses. 1994;37(7–8):285–9.PubMedGoogle Scholar
  13. 13.
    Warris A, Weemaes CM, Verweij PE. Multidrug resistance in Aspergillus fumigatus. N Engl J Med. 2002;347(26):2173–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Xiong QB, Hassan SA, Wilson WK, Han XY, May GS, Tarrand JJ, et al. Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors. Antimicrob Agents Chemother. 2005;49(2):518–24.CrossRefPubMedGoogle Scholar
  15. 15.
    Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science. 2005;309(5744):2185–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other aspergillus species. J Clin Microbiol. 2001;39(7):2431–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14 alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003;47(3):1120–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother. 2008;52(7):2468–72.CrossRefPubMedGoogle Scholar
  19. 19.
    Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents. 2006;28(5):450–3.CrossRefPubMedGoogle Scholar
  20. 20.
    Verweij PE, Mellado E, Melchers WJG. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356(14):1481–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJG, Verweij PE, Cuenca-Estrella A, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51(6):1897–904.CrossRefPubMedGoogle Scholar
  22. 22.
    Garcia-Effron G, Dilger A, Alcazar-Fuoli L, Park S, Mellado E, Perlin DS. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol. 2008;46(4):1200–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Bretagne S, Costa JM. Towards a molecular diagnosis of invasive aspergillosis and disseminated candidosis. Fem Immunol Med Mic. 2005;45(3):361–8.CrossRefGoogle Scholar
  24. 24.
    Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis. 2005;5(10):609–22.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  1. 1.Department of Dermatology, Peking University First Hospital, and Research Center for Medical MycologyPeking UniversityXicheng District, BeijingChina

Personalised recommendations